Skip Navigation



JAC Advance Access published online on March 2, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki053
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/4/528    most recent
dki053v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yu, J.
Right arrow Articles by Kadurugamuwa, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, J.
Right arrow Articles by Kadurugamuwa, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Received October 14, 2004
Revised January 6, 2005
Accepted January 7, 2005

Original article

Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model

Jun Yu 1*, Jenny Wu 1, Kevin P. Francis 1, Tony F. Purchio 1, and Jagath L. Kadurugamuwa 1

1 Xenogen Corporation, 860 Atlantic Avenue, Alameda, CA 94501, USA

* To whom correspondence should be addressed.
Jun Yu, E-mail: Jun.Yu{at}xenogen.com


  Abstract

Objectives: To investigate in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm model using bioluminescence imaging.

Materials and methods: S. aureus was engineered with a luciferase operon to emit bioluminescence that can be detected in vivo using an IVIS® imaging system. Two rifampicin-resistant strains of S. aureus that were previously isolated from animals undergoing rifampicin treatment, S464P (resistant to low concentrations of rifampicin) and H481Y (resistant to high concentrations of rifampicin), were characterized and then compared with their parental strain for in vivo fitness to form biofilm infections in the absence of rifampicin.

Results: The mutant S464P showed better adaptation to in vivo growth than either the parental strain or H481Y without selective pressure. Six days after implanting pre-colonized catheters, bioluminescent signals were seen from 100% of the catheters coated by the mutant S464P. In comparison, only 83% and 61% of the catheters coated by the parental strain and H481Y, respectively, maintained a signal in vivo. Rifampicin treatment of S464P biofilms in vivo resulted in a slight decline, but earlier rebound in bioluminescence from these catheters compared with the parental signal, whereas rifampicin had no affect on bioluminescence in mice infected with mutant H481Y.

Conclusions: The mutant with low-level rifampicin resistance appears to be better adapted to in vivo growth than the mutant that has high-level rifampicin resistance. Moreover, the former mutant may actually have a slight competitive advantage over the rifampicin-susceptible strain (parental), raising awareness for the occurrence of such strains in clinical environments.

Keywords: bioluminescence; animal models; imaging; IVIS.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
F. Goldstein
The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus
J. Antimicrob. Chemother., January 1, 2007; 59(1): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. K. Murphy, S. Mullin, M. S. Osburne, J. van Duzer, J. Siedlecki, X. Yu, K. Kerstein, M. Cynamon, and D. M. Rothstein
In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 827 - 834.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.